Advertisement

Topics

Axovant Sciences ‘emphasizes reboot’ with gene therapy, says Oppenheimer

07:53 EDT 13 Jun 2018 | Proactive Investors

Axovant expects to initiate a study of AXO-Lenti-PD in patients with advanced Parkinson's disease by the end of 2018

Original Article: Axovant Sciences ‘emphasizes reboot’ with gene therapy, says Oppenheimer

NEXT ARTICLE

More From BioPortfolio on "Axovant Sciences ‘emphasizes reboot’ with gene therapy, says Oppenheimer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...